Success Metrics

Active Trials
6(60%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
7
70%
Ph phase_3
1
10%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(9)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting3
Active, not recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 31 (10.0%)

Trials by Status

active_not_recruiting220%
unknown110%
recruiting440%
not_yet_recruiting330%

Recent Activity

6 active trials
Showing 5 of 10
recruitingphase_2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

NCT06649331
active_not_recruitingphase_2

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

NCT05924256
recruitingphase_2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT05582499
not_yet_recruitingphase_2

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

NCT06470672
recruitingphase_2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06649331Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
NCT05924256Phase 2

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Active Not Recruiting
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT06470672Phase 2

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not Yet Recruiting
NCT05594095Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
NCT05765032Phase 1

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Active Not Recruiting
NCT06394492Phase 3

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting
NCT06465238Phase 2

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not Yet Recruiting
NCT06433609Phase 2

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Not Yet Recruiting
NCT05154604Phase 1

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10